Climb Bio Stock Last Dividend Paid
| CLYM Stock | 1.95 0.08 3.94% |
Climb Bio fundamentals help investors to digest information that contributes to Climb Bio's financial success or failures. It also enables traders to predict the movement of Climb Stock. The fundamental analysis module provides a way to measure Climb Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Climb Bio stock.
Climb | Last Dividend Paid |
Climb Bio Company Last Dividend Paid Analysis
Climb Bio's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Climb Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Climb Bio is extremely important. It helps to project a fair market value of Climb Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Climb Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Climb Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Climb Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Climb Bio has a Last Dividend Paid of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Climb Fundamentals
| Net Income | (35.12 M) | ||||
| Total Debt | 2.87 M | ||||
| Total Asset | 110.47 M | ||||
| Retained Earnings | (155.98 M) | ||||
| Working Capital | 107.42 M | ||||
| Net Asset | 110.47 M |
About Climb Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Climb Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Climb Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Climb Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Climb Bio Piotroski F Score and Climb Bio Altman Z Score analysis. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.